Jim Cramer advises investors to view the recent market rotation as a buying opportunity for high-quality stocks that were unfairly sold off due to institutional portfolio shifts. He highlights companies such as Johnson & Johnson, PepsiCo, Starbucks, Constellation Brands, and TJX as undervalued despite solid business fundamentals. This rotation followed a slowdown in June job growth, prompting large investors to reposition holdings, which temporarily depressed these stocks. Cramer believes these conditions offer a chance to buy strong companies at a discount ahead of their upcoming earnings reports.
Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
With the 10-Year Treasury yield at 4.74%, dividend stocks must offer durable income. Dividend Aristocrats, companies with 25+ years of dividend increases, remain reliable for retirement income. Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo,...
The FDA has approved IMAAVY (nipocalimab-aahu) for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older, marking the first therapy specifically proven safe and effective for this rare, life-threatening disease. IMAAVY works...
Johnson & Johnson (JNJ) reported a 6.6% revenue increase to $25.3 billion in Q2 2026, driven by strong sales of key drugs DARZALEX and TREMFYA. The company raised its full-year 2026 guidance, supported by pipeline advancements including CAPLYTA's lab...
